MAIA (MAIA Biotechnology Inc.) stock: $1.05, $64.8M market cap, $27.6M cash, $37.2M EV, $95.1M fully diluted market cap. Next expected readout: Jul-27. Lead program: 6-Thio-2'-Deoxyguanosine (Carcinoma, Non-Small -Cell Lung), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Our Company MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2 ‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 3 · ActiveModality: small molecule (telomere-targeting nucleoside analog)
Aliases THIO, 6-thio-2'-deoxyguanosine, 6-thio-dG
Target telomeres / telomerase
Partnerships Regeneron (THIO-101 NSCLC trial with cemiplimab); BeOne Medicines (planned THIO-102 trials with tislelizumab in HCC, SCLC and CRC; BeOne funds trials and provides tislelizumab); Roche (trials with atezolizumab); UTSW (exclusive worldwide license to THIO; second license to additional compound)
Indications
Third-line non-small cell lung cancer (NSCLC)(Phase 3)
NSCLC resistant to checkpoint inhibitors and chemotherapy(Phase 2)
Hepatocellular carcinoma (HCC)(Phase 2)
Small cell lung cancer (SCLC)(Phase 2)
Colorectal cancer (CRC)(Phase 2)
Other solid tumors (breast, prostate, gastric, pancreatic)(Discovery)
Status note Lead asset. Phase 3 THIO-104 pivotal trial in 3L NSCLC; first patient dosed December 2025. Phase 2 THIO-101 in NSCLC Parts A/B/C; Part C international enrollment completed June 2026. FDA Fast Track designation for NSCLC (July 2025).
Second-generation ateganosine prodrugs
Discovery · ActiveModality: small molecule (telomere-targeting)
Aliases MAIA-2021-20, MAIA-2022-12
Target Telomere
Indications
Cancer (relapsed and refractory)(Discovery)
Status note Pipeline of seven compounds that completed in vitro evaluation; lead MAIA-2021-20 and backup MAIA-2022-12 nominated for GLP-toxicity and other preclinical studies, with Phase 1 trials planned.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.